Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

In this issue: The Big Picture: Is Biotech Dead Money? In Depth: New EBIS Pick:  Whitewave Foods (WWAV) – Food. Science. Momentum. Special Situation Trading Portfolio: Biotech ETF Short Term Trade Details Long Term Holding EBIS Portfolio:  VIVO News, Breakout – Updated Buy Range News and Analysis: Biosimilars:  Behind the… Read More

In this issue: The Big Picture: Is Biotech Dead Money? In Depth: New EBIS Pick:  Whitewave Foods (WWAV) – Food. Science. Momentum. Special Situation Trading Portfolio: Biotech ETF Short Term Trade Details Long Term Holding EBIS Portfolio:  VIVO News, Breakout – Updated Buy Range News and Analysis: Biosimilars:  Behind the… Read More

Food. Science. Momentum.In the emerging world of applied science, Whitewave Food (NYSE: WWAV), a spinoff from Dean Foods is prototypical of an emerging sector, that of applied science without the emphasis on electronic products such as phones and PCs.  The company harnesses the power of nature with its focus on… Read More

Food. Science. Momentum.In the emerging world of applied science, Whitewave Food (NYSE: WWAV), a spinoff from Dean Foods is prototypical of an emerging sector, that of applied science without the emphasis on electronic products such as phones and PCs.  The company harnesses the power of nature with its focus on… Read More

Our foray into UBIO, the leveraged long biotech ETF,  got a rough start.  But those investors who have owned BIS, the inverse leveraged biotech ETF, especially simultaneously with UBIO have fared better overall since BIS shares have risen during the period in which UBIO has fallen. We still think that biotech… Read More

Our foray into UBIO, the leveraged long biotech ETF,  got a rough start.  But those investors who have owned BIS, the inverse leveraged biotech ETF, especially simultaneously with UBIO have fared better overall since BIS shares have risen during the period in which UBIO has fallen. We still think that biotech… Read More